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peer pressure, for marketing purposes, or without prop-
er training and supervision. The STS/AATS Committee
on New Technology specifically condemns the perfor-
mance of MICAB only for marketing purposes. The
results obtained by using conventional open techniques
must be matched by MICAB techniques.
MICAB is essentially a reconfiguration of a number
of established and accepted cardiac surgical techniques
using new incisional and anatomic approaches, rather
than a new procedure to establish myocardial revascu-
larization. Minimally invasive techniques continue to
evolve and may now include a variety of stabilization
and/or visual enhancement systems. MICAB must un-
dergo rigorous evaluation for comparison to the estab-
lished results of conventional coronary bypass. Patients
must be fully informed of the differences between con-
ventional grafting and the minimal-access grafting.
Surgeon and center experience must be discussed. Graft
patency data should be collected to help identify differ-
ences that may ultimately become significant and to
establish the role of these techniques in the surgical
treatment of coronary artery disease.
The different approaches required for MICAB and the
problematic issues of performing precise anastomoses
either on the beating heart or through small incisions on
the arrested heart during CPB make the issue of surgical
education particularly important. As the various
approaches to MICAB evolve, a profusion of new tech-
niques and equipment has appeared. A surgeon wishing
to adopt these new techniques or technologies should
attend one or more CME approved courses that conform
to the STS/AATS Ad Hoc Committee on New Tech-
nology Assessment educational guidelines. These cours-
es should include didactic sessions, and may include
video sessions, ideally interspersed with laboratory expe-
rience to master specific techniques. Observation of min-
imally invasive surgery at experienced centers is now
possible and is strongly encouraged.
MICAB will continue to evolve over the next several
years and new or hybrid procedures and new technolo-
gies will likely emerge. As this occurs, it is incumbent
on practitioners to appropriately educate themselves, as
well as to document and disseminate new information.
The Joint Committee strongly recommends that perfor-
mance of these procedures be currently restricted to
M inimally invasive coronary artery bypass(MICAB) procedures with or without cardiopul-
monary bypass (CPB) are approaches for surgical coro-
nary revascularization designed to reduce operative
trauma, speed patient recovery, allow faster return to
normal activity, and achieve cost containment as com-
pared with conventional coronary bypass grafting.
Minimally invasive direct coronary bypass (frequently
referred to as MIDCAB) is an approach that does not
use CPB or cardioplegia. Most commonly, a small left
anterior thoracotomy is made and the left internal tho-
racic artery is harvested and anastomosed to the left
anterior descending coronary artery on the beating
heart. Although single-vessel bypass has been done in
more than 90% of the cases, multiple grafting can be
accomplished in some circumstances. The use of com-
plete sternotomy with multivessel bypass on the beating
heart without CPB is also an option (frequently referred
to as OPCAB), and some have referred to this as “min-
imally invasive” because CPB is not used. Another
approach to minimal-access coronary artery bypass
grafting is to employ CPB. In this instance, the opera-
tion (frequently referred to as PA-CAB) is performed
through a limited thoracic incision, but also using Port-
Access technology. CPB is established through periph-
eral cannulation. Cardioplegia is administered after aor-
tic occlusion with an Endoaortic balloon clamp, and
Port-Access techniques are used for insertion of thora-
coscopic and special instruments. Finally, minimally
invasive coronary artery bypass can also be performed
with CPB through the same incisions, but without aor-
tic occlusion, using ventricular fibrillation and immobi-
lization of the coronary arteries.
The premise for adopting these less invasive ap-
proaches to coronary grafting is that patient morbidity
can be reduced without reducing the safety or efficacy
of the coronary bypass operation. At this early stage in
the minimally invasive coronary bypass experience,
considerable data are being generated. Clearly, MICAB
is misused if it is performed for cosmesis, as a result of
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established cardiac surgical programs staffed by board-
certified cardiothoracic surgeons who are skilled in the
performance of conventional cardiac operations. It is
also strongly recommended that these procedures be
monitored closely for morbidity and mortality by estab-
lished hospital quality assurance committees. Such
monitoring should include documentation of complica-
tions and long-term outcome, especially as these fac-
tors relate to conventional coronary bypass surgery.
The STS/AATS Ad Hoc Committee on New Tech-
nology Assessment is available to consult with organi-
zations such as the National Institutes of Health, Food
and Drug Administration, Health Care Financing
Administration, Joint Commission on Accreditation of
Healthcare Organizations, and American Board of
Thoracic Surgery on questions relating to the perfor-
mance and evaluation of the operation, as well as the
training of the surgeons who perform MICAB.
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